TROG Trial Portfolio Update (March 2020)
New proposals - submission process
All completed trials
TROG Trial Portfolio Summary (March 2019)
Our values are collaboration, quality and care.
An international study (BIG 3-07/TROG 07.01) shows that after breast conserving surgery, higher radiation doses to the part of the breast where the DCIS was found, in addition to radiotherapy of the whole breast, significantly reduced its risk of returning in patients with higher-risk DCIS.
The diagnosis of ductal carcinoma in situ (DCIS) of the breast has increased substantially due to mammographic screening, and now accounts for 25 per cent of screen-detected breast cancer. Over 1,600 women are diagnosed with DCIS in Australia every year. However, unlike invasive breast cancer, there are limited knowledge and experience for patients and clinicians to draw on when this now common diagnosis of DCIS is made.
Prostate cancer is one of the most common cancers amongst men, with one in six men diagnosed before their 85th birthday (Cancer Australia). In fact, in 2019 alone over 19,000 men in Australia were diagnosed with prostate cancer.
p style="text-align: center;">_ src="/sitefiles/trogcomau/trog_team_2020.jpg" style="height: 333px; width: 500px;" />
covid-19 and the regulations around social distancing has affected an increasing number of events across australia, including the yearly gathering of radiation...
The coronavirus health pandemic is a challenging time for us all – personally and professionally.
We know that the changes and safety precautions required as a result of the pandemic have had significant impacts on the way we operate clinical trials – those that are underway, set t...
_ src="/sitefiles/trogcomau/fbp_0378_large.jpg" />
new research by the university of new south wales (unsw), presented at the clinical oncology society of australia’s (cosa) annual scientific meeting (asm) found that increased use of radiation therapy for prostate cancer patients c...
trog cancer research will work with clinicians at townsville hospital, as well as other national experts, to implement a research program aimed at understanding how to best use new mri linac technology to benefit cancer patients.
TROG Cancer Research is currently in the final year of their 2017-2019 strategic plan. On Friday 2 August 2019, we held a strategic planning meeting with key stakeholders to discuss the direction and focus for the upcoming three years. The workshop facilitated by Ms Alison Evans, Hea...
trog cancer research are proud to announce that we have two new additions to the trog cancer research board of directors.
joining our team is professor annette haworth and denis byron.
appointed as a non-radiation oncology director, annette is an accredited medical physicist wh...